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Abstract
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New
approaches for risk stratification beyond tumor stage are needed. Gene expression-
based AC subtypes such as the Cancer Genome Atlas Network (TCGA) terminal-
respiratory unit (TRU), proximal-inflammatory (PI) and proximal-proliferative
(PP) subtypes have been associated with prognosis, but show methodological limita-
tions for robust clinical use. We aimed to derive a platform independent single sample
Abbreviations: AC, adenocarcinoma; CLAMS, Classification of Lung Adenocarcinoma Molecular Subtypes; DMFS, distant metastasis-free survival; FFPE, formalin-fixed paraffin-embedded; NCC,
nearest centroid classification; NSCLC, nonsmall cell lung cancer; OS, overall survival; PI, proximal-inflammatory; PP, proximal-proliferative; SSP, single sample predictor; TRU, terminal-
respiratory unit.
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Skåne/ALF) predictor (SSP) for molecular subtype assignment and risk stratification that could
function in a clinical setting. Two-class (TRU/nonTRU=SSP2) and three-class (TRU/
PP/PI=SSP3) SSPs using the AIMS algorithm were trained in 1655 ACs (n = 9659
genes) from public repositories vs TCGA centroid subtypes. Validation and survival
analysis were performed in 977 patients using overall survival (OS) and distant
metastasis-free survival (DMFS) as endpoints. In the validation cohort, SSP2 and
SSP3 showed accuracies of 0.85 and 0.81, respectively. SSPs captured relevant biol-
ogy previously associated with the TCGA subtypes and were associated with progno-
sis. In survival analysis, OS and DMFS for cases discordantly classified between
TCGA and SSP2 favored the SSP2 classification. In resected Stage I patients, SSP2
identified TRU-cases with better OS (hazard ratio [HR] = 0.30; 95% confidence inter-
val [CI] = 0.18-0.49) and DMFS (TRU HR = 0.52; 95% CI = 0.33-0.83) independent of
age, Stage IA/IB and gender. SSP2 was transformed into a NanoString nCounter
assay and tested in 44 Stage I patients using RNA from formalin-fixed tissue, provid-
ing prognostic stratification (relapse-free interval, HR = 3.2; 95% CI = 1.2-8.8). In con-
clusion, gene expression-based SSPs can provide molecular subtype and independent
prognostic information in early-stage lung ACs. SSPs may overcome critical limita-
tions in the applicability of gene signatures in lung cancer.
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1 | INTRODUCTION
Lung adenocarcinoma (AC) is the most frequent histological type of
nonsmall cell lung cancer (NSCLC).1 Compared to other NSCLC
tumors, AC tumors have been associated with specific molecular and
etiological traits, including a nonsmoking patient history and onco-
genic driver alterations (eg, EGFR mutations and various fusion
genes).2-5 In advanced-stage AC, immune checkpoint and tyrosine
kinase inhibitors are now clinical routine. In surgically treated cases,
chemotherapy remains the main adjuvant treatment option, guided by
the TNM classification.6 Despite an overall favorable prognosis, surgi-
cally treated lung cancer is still associated with a high-risk of meta-
static relapse, even for tumors of the lowest stage (Stage I).7 Based on
the lack of significant survival benefit in Stage IA disease,8 adjuvant
therapy was not recommended for this particular group, while Stage
IB patients may receive treatment. Clearly, additional prognostic and
predictive tools are needed to improve therapy decisions in surgically
treated AC.
Surgically resected AC has been intensively studied using differ-
ent high-throughput molecular profiling techniques. Gene expression-
based studies have reported prognostic gene signatures and
suggested the existence of molecular subtypes in AC.4,9-15 The TCGA
study on AC concluded three transcriptional subtypes termed the
terminal-respiratory unit (TRU), the proximal-inflammatory (PI) and
the proximal-proliferative (PP) subtypes.4,9 These subtypes have been
associated with different clinicopathological and molecular variables,
but also patient outcome.9,13 Specifically, the TRU subtype shows
overrepresentation of patients with a nonsmoking history, tumors
with EGFR mutations, tumors of lower stage, lower tumor proliferation
in general, and importantly improved patient outcome.4,9,13 In con-
trast, both the PI and PP subtypes are associated with a patient
smoking history and show features of often aggressive disease,
including high frequencies of different nontargetable driver mutations,
What's New?
New tools are needed in order to improve risk stratification
and therapy selection in early-stage lung adenocarcinoma.
Inherent differences in gene expression between adenocar-
cinoma subtypes could facilitate the development of such
tools. The authors of this study derived platform-indepen-
dent, single-sample predictors (SSP) of adenocarcinoma sub-
types, based on gene expression. Derived SSPs successfully
provided prognostic information in surgically treated stage I
lung adenocarcinoma patients. The single-sample classifier
was readily translated into assays applicable to archival tis-
sue, indicating clinical utility. The findings highlight the clini-
cal relevance of transcriptional signatures and gene
expression predictors in lung adenocarcinoma, warranting
their further investigation and development.
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higher proliferation and specific morphologic growth patterns.4,9,13
Recent large-scale analyses have demonstrated that, based on current
treatment options (surgery with or without chemotherapy/radiother-
apy), the robust prognostic power of the gene expression subtypes
lies in the two-class distinction of TRU vs nonTRU samples and is
mainly related to differences in expression of proliferation-associated
genes.13
The current classification scheme for TRU, PI and PP subtypes
involves classification of a new sample according to the nearest cen-
troid classification (NCC) approach.9 While NCC type classifiers have
been used extensively for classification of tumors (eg, the PAM50
classifier in breast cancer16), this type of classifier presents some limi-
tations concerning the prediction of independent samples.13,17-19 Ide-
ally, a single sample predictor (SSP) that does not require any
preprocessing, is independent of gene expression platform and capa-
ble of predicting a single sample is desirable. In this context, predictors
based on gene rules assessed on an intrasample basis have been pro-
posed as a solution.17,18,20-22
In our study, we aimed to derive SSPs of the TRU/nonTRU and
TRU/PI/PP subtypes. Using machine-learning in 1655 AC cases and
independent validation in 977 AC cases we developed a 36-gene SSP of
the TRU/nonTRU subtypes. This SSP provided refined prognostic cate-
gorization of patients compared to the existing classification approach
and also independent prognostic information in surgically treated Stage I
AC. As a proof of concept, the SSP was translated into a NanoString
nCounter XT assay and tested in archival tissue specimens (formalin-
fixed paraffin-embedded [FFPE]) for prediction of disease relapse.
2 | MATERIALS AND METHODS
2.1 | Patient datasets
Twenty-two publicly available gene expression datasets (n = 2632
samples) were assembled. Forty-three samples overlapped between
two datasets. Complete datasets (ie, all samples) were partitioned into
an SSP training cohort (n = 17 datasets, n = 1655) or a validation
cohort (n = 5 datasets, n = 977) (Figure 1). Partitioning was directed
toward having training and validation cohorts with mixed technical
platforms, and that the validation cohort should include both patients
with only surgical treatment and patients with adjuvant chemother-
apy, to allow relevant outcome analyses. Clinicopathological charac-
teristics for training and validation datasets are outlined in Table 1,
based on data from original studies. Mutation status (EGFR/KRAS, etc.)
for these public cohorts is highly limited.
To test SSPs in FFPE, two cohorts were used. First, Fragments
Per Kilobase of transcript per million mapped reads data were
obtained from the GSE143486 dataset, representing 30 RNA
sequenced Stage I ACs with no adjuvant therapy. Secondly, RNA from
a cohort of 44 patients, diagnosed between 2006 and 2015 at differ-
ent Nordic institutions, with surgically treated Stage I AC were col-
lected. The 44 patients were selected using a “case-control” approach
based on recurrence (locoregional and/or distant) to fit with the
NanoString multiplexing scheme. Twenty-three patients presented
with recurrence within 5 years from diagnosis (56.5% Stage IA, 43.5%
IB), and 21 were recurrence-free 5 years from diagnosis (76% Stage
IA, 24% IB), thus forming two patient groups: (a) “poor” (case) and
(b) “better” (control) outcome. Patients in the two groups were
selected to balance gender, smoking status and original patient institu-
tion. The selection was verified through statistical testing, finding no
statistically significant difference in gender, smoking status or Stage
IA/IB (Fisher's exact test >0.05). Clinicopathological variables were
collected from patient charts. Complete clinical mutation/gene fusion
status was not available for this retrospective cohort.
2.2 | Pathology assessment of lung AC growth
patterns
Assessment of histological growth patterns were assessed in patients
from Karlsson et al36 (GSE60644, n = 16) and Djureinovic et al37
(GSE81089, n = 110) as reported in Salomonsson et al.43 Briefly, all his-
tological slides were reviewed for each case for investigation of growth
patterns. The cases were graded according to predominant growth pat-
tern: lepidic predominant (incl. minimally invasive AC) were classified as
low grade, acinary and papillary predominant as medium grade and
micropapillary and solid predominant or invasive mucinous AC as high
grade (Reference 44 and the WHO classification from 2015).
2.3 | Preprocessing and TCGA NCC classification
of gene expression data
Preprocessing of gene expression data was performed as described in
Cirenajwis et al.22 Common gene symbols across the 22 datasets were
extracted (n = 9659) to create a uniform expression matrix. To gener-
ate training/reference classes for the SSPs, NCC was performed for
each dataset separately to assign each sample a TCGA subtype (TRU,
PI or PP) based on the highest (Pearson) correlation as described else-
where.9,22 In addition, a two-class constellation consisting of TRU vs
nonTRU cases was also generated and used for SSP training.
2.4 | AIMS single sample classifier
The AIMS17 method was implemented using source scripts available
from the GitHub repository (https://github.com/meoyo/trainAIMS).
Training was performed on raw gene expression data (n = 9659 genes)
from the 1655 training samples as outlined in Cirenajwis et al22 with
the exception for the Lee et al and CLCGP datasets for which only
normalized gene expression data could be obtained from public repos-
itories. Briefly, the training cohort was trained against either the two-
class (TRU/nonTRU) or three-class (TRU/PI/PP) constellations to
generate the AIMS-based predictors referred to as SSP2 or SSP3,
respectively. No further preprocessing of gene expression data was
performed. To avoid unequal rule contribution in rule selection due to
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size differences across datasets for the merged training cohort,
the AIMS algorithm applied a weighted form of rule selection pro-
vided by the R package “Rgtsp.” The derived SSP2 and SSP3 models
will be available as an R package “Classification of Lung Adenocarci-
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F IGURE 1 Flow-chart of study. A, Approach to derive molecular subtype training class through nearest centroid classification (NCC) of all
datasets individually using the scheme reported by Wilkerson et al.9 For the two-class subtype approach, PP and PI subtypes were combined to a
single nonTRU class. B, Training and validation scheme for deriving a two-class SSP for TRU/nonTRU (SSP2) and a three-class SSP for TRU/PI/PP
subtypes (SSP3) based on the AIMS single sample method. Of the total 22 datasets included, 5 were reserved as independent validation datasets
and were also used for evaluation of prognostic performance of the SSP models in both surgically treated only and adjuvantly treated patients. A
patient overlap existed for the Shedden et al and Zhu et al cohorts. Patients overlapping were excluded from one cohort in survival analyses. An
additional external validation of the SSP2 model was also performed in archival RNA from 44 Stage-I patients treated with surgery only, by
pairing the SSP2 model with the NanoString nCounter XT technology
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2.5 | Pathway analysis
Pathway analysis was performed using the PANTHER Classification Sys-
tem (http://pantherdb.org) and the overrepresentation test application
to identify significant biological pathways covered by the SSPs. Default
settings were used, and gene ontology terms with a false discovery rate
adjusted Fisher's exact test P < .05 were considered significant.
2.6 | A NanoString SSP gene expression assay
To test the applicability of CLAMS in archival tissue (ie, RNA from
FFPE tissue), a NanoString (www.nanostring.com) nCounter XT assay
was designed based on the CLAMS genes for TRU/nonTRU (SSP2)
prediction. RNA from FFPE tissue was extracted using the AllPrep
DNA/RNA FFPE Kit (Qiagen, Hilden, Germany). A 300 ng RNA was
used in the nCounter XT CodeSet Gene Expression Assay and counts
were generated on a SPRINT instrument after the manufacturer's
instructions (NanoString Technologies, Seattle, WA). Four cartridges
(12-sample) were run with 44 samples and 4 controls in total. Gener-
ated counts were background corrected and generated gene expres-
sion data were quality assessed as described.45,46 All samples passed
quality thresholds.
2.7 | Statistical analysis
All statistical analyses were performed as two-sided tests using R
(www.r-project.org). Classification performance (accuracy and bal-
anced accuracy) for SSP2 and SSP3 were analyzed in each validation
dataset separately. For analysis of individual gene expression across
the molecular subtypes in the validation cohort (n = 934, no


















Chitale et al23 a 102 Chitale U133
2plus
Affymetrix 41 69 Yes No 0 41 Training
CLCGP24 b 98 CLCGP Illumina 48 44 Yes Yes 0 34 Training
Bild et al25 58 GSE3141 Affymetrix NA 45 Yes Yes 0 36 Training
Lee et al26 63 GSE8894 Affymetrix 54 NA No Yes 0 38 Training
Tomida et al27 117 GSE13213 Agilent 51 68 Yes No 0 40 Training
Hou et al28 45 GSE19188 Affymetrix 56 NA Yes No 0 31 Training
Lu et al29 60 GSE19804 Affymetrix NA 58 No No 0 38 Training
Wilkerson et al9 116 GSE26939 Agilent 46 53 Yes No 0 41 Training
Rousseaux et al30 85 GSE30219 Affymetrix 78 95 Yes Yes 0 34 Training
Botling et al31 106 GSE37745 Affymetrix 43 66 Yes No 0 35 Training
Seo et al32 87 GSE40419 RNAseq 61 63 No No 0 41 Training
Tarca et al33 77 GSE43580 Affymetrix 68 53 No No 0 42 Training
Chen et al34 92 GSE46539 Illumina 17 NA No No 0 37 Training
Der et al35 127 GSE50081 Affymetrix 51 72 Yes Yes 0 39 Training
Karlsson et al36 77 GSE60644 Illumina 42 88 Yes No 0 40 Training
Djureinovic
et al37
115 GSE81089 RNAseq 37 58 Yes No 0 35 Training
TCGA4 c 230 TCGA RNAseq NA NA No No 0 39 Training
Shedden et al38 444 Shedden Affymetrix 50 62 Yes Yes 89 37 Validation
Okayama et al39 226 GSE31210 Affymetrix 46 74 Yes Yes 0 43 Validation
Fouret et al40 d 103 E-MTAB-923 Affymetrix 16 58 Yes No 33 42 Validation
Zhu et al41 e 71 GSE14814 Affymetrix 52 59 Yes Yes 39 35 Validation
Tang et al42 133 GSE42127 Illumina 51 67 Yes No 39 38 Validation
aSamples were divided into two cohorts based on the different Affymetrix platforms, U133A and U133 2plus. Only the latter subset was included in the
analysis.
bCLCGP, The Clinical Lung Cancer Genome Project (http://www.uni-koeln.de/med-fak/clcgp/).
cThe Cancer Genome Atlas Network (TCGA).
dData obtained from the “ArrayExpress” database (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-923/).
ePresent dataset overlaps with Shedden et al (43 samples).
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overlapping samples), genes were ranked (from 1 to 9659) sample-
wise using the function “rankGenes” provided by the R package
“singscore” (version 1.5.0).47
2.8 | Survival analysis
Survival analyses were performed using the R “survival” package (ver-
sion 2.43.1) with overall survival (OS), distant metastasis-free survival
(DMFS) or recurrence-free interval (for NanoString FFPE samples) as
endpoints defined according to original studies (Table 1). Survival cur-
ves were compared using Kaplan-Meier estimates and the log-rank
test. Hazard ratios (HR) were calculated through univariable or multi-
variable Cox regression using the “coxph” R function. Survival data
was censored at 5 years to account for differences in follow-up time
between validation datasets.
3 | RESULTS
3.1 | Clinical and molecular subtype characteristics
of the patient cohort
Twenty-two reported gene expression datasets for lung AC (n = 2632
patients in total) were divided into a training cohort (n = 1655) and a
validation cohort (n = 977) (Figure 1, Table 1). All datasets were classi-
fied on a per cohort basis, according to TCGA TRU/PP/PI subtypes by
the NCC method. Similar proportions of subtypes were observed
across the datasets (Figure 2A), despite substantial differences in, for
example, distribution of tumor stage and technical platform (Table 1).
This observation is an illustration of the inherent feature of NCC clas-
sification relying on gene centering across samples, which if not
accounted for make sample classification cohort dependent.13,22 Still,
TCGA NCC subtypes retained reported associated clinical features,4,9
including a higher proportion of Stage I tumors, never-smokers and
patients with EGFR mutations in TRU-classified tumors in both train-
ing and validation cohorts (Supplementary Figure S1).
3.2 | Deriving SSPs for TCGA lung AC subtypes
Based on TCGA NCC subtypes for 1655 training samples and 9659
genes present across all datasets, AIMS17 was used to derive a two-
class SSP for TRU vs nonTRU samples (SSP2) and a three-class SSP
for the TRU/PI/PP subtypes (SSP3). SSP2 consisted of 18 gene rules
(n = 36 unique genes), while SSP3 consisted of 47 gene rules per sub-
type (n = 141 gene rules in total, n = 259 unique genes) (Figure 2B;
Supplementary Table S1). Reclassification of the 1655 training sam-
ples showed an accuracy of 0.85 for SSP2 and 0.82 for SSP3 vs TCGA
NCC classifications, acknowledging the circular nature of this analysis.
Fifty-six percent (20/36) of the SSP2 model genes overlapped with
the original 506 NCC genes, and 83% (15/18) of gene rules involved at
least one NCC gene (Figure 2C). For SSP3, corresponding values were
56% (144/259 genes) and 79% (112/141 gene rules). Functional analy-
sis of SSP gene rules were investigated by gene set enrichment analysis
(Supplementary Table S2). For the SSP2 model, selected genes were
strongly enriched for the cell cycle gene ontology process. For the
SSP3 model, additional significant gene ontology processes, besides the
cell cycle, included leukocyte migration and chemotaxis, extracellular
matrix and structure, cell migration and localization terms.
For two cohorts (Karlsson et al36 and Djureinovic et al37) in the
training dataset, we had access to reviewed pathology assessments of
histological lung AC growth patterns (lepidic predominant, acinary and
papillary predominant, and micropapillary and solid predominant) for
126 cases. Cross tabulation of SSP2 classifications vs these histologi-
cal subtypes revealed that 87.5% of cases with lepidic predominant
growth patterns were of the TRU subtype. For TRU cases, 14.3% had
lepidic growth patterns, 71.4% acinary and papillary predominant
growth patterns and 14.3% micropapillary and solid predominant
growth patterns. Corresponding values for nonTRU cases were 1.3%,
63.6% and 35.1% (Fisher's exact test, P = .001). When excluding the
small number of lepidic cases, corresponding values were 83.3%
acinary and papillary predominant patterns, and 16.7% micropapillary
and solid predominant patterns in TRU classified cases, and 64.5%
and 35.5%, respectively, in nonTRU cases (Fisher's exact P = .035).
These general patterns were retained also when viewing the individ-
ual datasets, although not reaching statistical significance due to lower
numbers. Together, these results indicate an association of the SSP
classifications with histological AC growth patterns.
3.3 | Validation of SSP2 and SSP3 as predictors of
AC molecular subtype
SSP2 and SSP3 models were validated in 977 independent samples
derived from five datasets analyzed by either Illumina or Affymetrix
gene expression microarrays (Table 1, Figure 1). Importantly, the
SSP2/SSP3 models do not rely on any preprocessing, thus new sam-
ples are classified independently based on raw data only.
Per validation dataset, the proportion of TRU classified samples
for the NCC vs SSP2 model was first compared (Figure 2D). Differ-
ences were observed for specific datasets. The Okayama et al48
dataset showed a notably higher fraction of SSP2-TRU samples than
the NCC classifier, a pattern partly also present in the Fouret et al40
and Tang et al42 datasets. Across all validation samples, an accuracy of
0.85 for SSP2 and 0.81 for SSP3 were observed when compared to
NCC subtypes. Variations between individual datasets in accuracy
were observed as outlined in Figure 2E.
3.4 | Clinical and molecular characterization of
discordantly classified samples by SSP and NCC
methods
In the 977-sample validation cohort, 137 cases (14%) were discor-
dantly classified between the NCC (2-class) and SSP2 models.
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This subset of patients had a higher proportion of never-smokers
(Fisher's exact test P = .02) and Stage II tumors (P = .0007) compared
to concordantly classified patients (Supplementary Figure S2A). To
further dissect discordant cases, all validation cases were given a label
corresponding to the class assignment by the two methods
(NCCstatus-SSPstatus). This formed four groups: (a) TRU-TRU (=concor-
dant TRU), (b) TRU-nonTRU, (c) nonTRU-TRU and (d) nonTRU-
nonTRU (=concordant nonTRU). Analysis of the MKI67 gene expres-
sion ranks (Ki67, a well-established proliferation-related gene) indi-
cated higher proliferation in the concordant nonTRU group as
compared to the concordant TRU group. For discordantly classified
cases, the MKI67 expression pattern was consistent with the SSP2
classification, meaning, for example, lower expression in nonTRU-TRU








































































































































































































































































































































           LY86 < UBE2C
CACNA2D2 < TPX2
         CD1C < KIF4A
     TGFBR3 < TRIP13
         CD1E < MCM10
     CYP4B1 < MCM2
            HLF < NDC80
       CDKL2 < PBK
         CBX7 < PRC1
      ADRB2 < CDKN3
      ADH1B < MKI67
      CDC20 < HSD17B6
        MELK < NR3C2
        EXO1 < FIGF
      AURKB < SCTR
          OIP5 < PLA2G1B
      CENPF < CLIC5
















































F IGURE 2 Training and validation of SSPs for prediction of molecular subtypes in lung adenocarcinoma. A, Proportion of TRU and nonTRU cases
predicted by the NCC method9 per dataset in the study. For each dataset, assignment to training or validation cohort and technical gene expression
platform is shown. Top-axis indicates dataset size. B, Schematic overview of the SSP2 classifier for TRU/nonTRU status based on training vs NCC
subtype classes in the training cohort. The SSP2 classifier comprises 18 gene rules (pairs), that is, 36 genes. Gene rules are shown with indication of
their highest posterior probability in the AIMS model. Based on all individual gene rule probabilities a final prediction is made. C, Overlap of genes in
the SSP2 (top) and SSP3 classifiers vs the original NCC centroid genes fromWilkerson et al.9 D, Proportions of TRU classified cases in the five
validation datasets for the NCC and SSP2 models, showing differences across datasets. E, Classification performance (accuracy and balanced
accuracy) in the validation cohort for the SSP2 model vs TRU/nonTRU NCC classifier, and the SSP3 model vs the TRU/PI/PP NCC classifications
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of discordant cases had an intermediate correlation (eg, between
0 and 0.2) to the TCGA NCC centroids (TRU/PI/PP) and were weakly
separated by the NCC method (Supplementary Figure S2C,D).
3.5 | Molecular subtype prediction by NCC and
SSP models vs patient outcome
Based on the prognostic analyses of TCGA NCC subtypes reported by
Ringner et al,13 outcome analysis was restricted to the TRU/nonTRU con-
text. Patients in the validation cohort were stratified by treatment status
into a prognostic group (n = 616 unique patients treated with surgery
alone) and an adjuvant chemotherapy treated group (n = 178 unique
patients) (Figure 1, Table 1). The four NCCstatus-SSPstatus groups were
used to address the question of which classifier appeared more “clinically
meaningful” for discordantly classified cases based on survival outcome.
In the prognostic arm, concordant TRU patients (including
patients of all stages) had an improved OS compared to concordant
nonTRU patients, with a 5-year survival rate of 82% vs 54%, respec-
tively (Figure 3A). The subset of patients (n = 104 in total, 16.9%) with
discordant NCC (2-class)/SSP2 class (TRU-nonTRU and nonTRU-TRU)
showed differences in OS (P = .0015, log-rank test) (Figure 3B). The
patient group classified as TRU by NCC and nonTRU by SSP2 (TRU-
nonTRU) had a similar survival pattern as the concordant poor out-
come nonTRU patient group (Table 2, Figure 3A). These patients had
a significantly increased risk of death (HR = 2.90; 95% confidence
interval [CI] = 1.37-6.32; P = .005), as compared to the concordant
TRU patient group. The reverse was observed for the nonTRU-TRU
patient group, which showed a survival pattern similar to that of the
concordant better outcome TRU group (Table 2, Figure 3A). Thus,
based on patient survival, discordantly classified patients seem to be
more “accurately” classified by the SSP2 model. Similar trends were
observed for DMFS, considering that this analysis included patients of
all stages (Table 2, Figure 3C,D).
In the adjuvant chemotherapy patient group, survival differences
between the concordant TRU and nonTRU groups were less pro-
nounced at 5 years postsurgery, with an OS rate of 57% and 45%,
respectively (Figure 3E). Herein, 12.9% (n = 23) had discordant subtype
labels. The slightly lower discordance rate may be due to that adjuvant
chemotherapy is selectively given to high-risk patients, which concep-
tually should more often be intrinsic nonTRU. Given the low number of
discordant cases, especially for the DMFS endpoint (Figure 3F), larger
datasets are needed to determine whether the findings in surgically
treated patients translate to adjuvant treated discordant patients.
3.6 | Association of patient outcome with SSP2
prediction in surgically treated Stage I disease
In surgically treated Stage I patients from the validation cohort, the
SSP2 predicted TRU patient group was significantly associated with a
better OS (89% 5-year survival) with a hazard ratio of 0.29 (95%
CI = 0.18-0.46; P < .0001), as compared to the nonTRU patient group
(65% 5-year survival) (Figure 4A). Of Stage IA patients with OS data,
73% were TRU-classified, while for Stage IB only 48% were TRU-clas-
sified. The better OS of TRU-classified cases remained significant also
in subgroups of Stage IA or IB patients (log-rank P = .007 and 90% 5-
year survival, and P = .0002 and 85% 5-year survival, respectively, and
was also observed independently of age and gender in Stage IA
(HR = 0.36; 95% CI = 0.17-0.75; P = .007) or Stage IB (HR = 0.26;
95% CI = 0.13-0.52; P = .0001).
In TRU-classified patients, Stage IA/IB was not associated with
differences in OS (log-rank P = .31). SSP2 classification added inde-
pendent prognostic information in a multivariable Cox regression
model for OS including age, Stage IA/IB, and gender as covariates for
Stage I patients (TRU HR = 0.30; 95% CI = 0.18-0.49; P < .0001). For
DMFS, SSP2 also significantly stratified patients into better (TRU, 5-
year DMFS = 79%) and worse (nonTRU, 5-year DMFS = 62%) out-
come (Figure 4B), supported by univariable (TRU HR = 0.48; 95%
CI = 0.31-0.74; P = .0008) and multivariable Cox regression analyses
using age, Stage IA/IB and gender as covariates (TRU HR = 0.52; 95%
CI = 0.33-0.83; P = .006).
3.7 | An assay based on SSP2 applicable to FFPE
tissue
To test our SSP2 model in FFPE tissue, we created an R-based imple-
mentation (referred to as CLAMS) and paired it with the NanoString
nCounter XT technology to create a “complete” assay. We applied this
assay to FFPE RNA from 44 Stage-I ACs treated surgically only.
Twenty-one of the patients were metastasis-free 5 years after diagno-
sis (forming a “better” prognosis group), while the remaining
23 patients had a relapse (loco-regional/distant) within 5 years (rep-
resenting a “poor” outcome group).
CLAMS prediction of the 44 cases classified 39% (17/44) as TRU
and 61% (27/44) as nonTRU (Supplementary Table S3, including all
data). Of TRU-classified samples 88% were Stage IA, while for non-
TRU 52% were Stage IA. Hierarchical clustering of raw counts for
CLAMS genes across the 44 cases confirmed the TRU/nonTRU
CLAMS subgroups (Figure 4C), further supported by gene rule fulfill-
ment for predicted cases (Supplementary Figure S3). CLAMS classifi-
cation was next compared to the two patient prognosis groups
(no relapse/relapse, Supplementary Table S3, Figure 4D). Of the TRU
classified patients, 71% were metastasis free after 5 years, in contrast
to only 33% of the nonTRU classified patients (accuracy for CLAMS
groups vs relapse status was 0.68). The specificity (no relapse in TRU
group) was 0.71, sensitivity (relapse in nonTRU group) was 0.67 and
the positive predictive value was 0.78 (relapse in poor group also
being nonTRU). For discrepant cases predicted as TRU but with
relapse, we observed slightly elevated expression of MKI67 and
lowered Napsin A expression (NAPSA), consistent with a more non-
TRU like phenotype. Moreover, nonTRU cases without relapse
showed elevated expression of MKI67, as compared to TRU cases, sig-
naling why these were likely classified as nonTRU by CLAMS
(Figure 4E).
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F IGURE 3 Comparison of classification methods and implication on survival outcome in lung adenocarcinoma. For details about the groups
used in the Kaplan-Meier plots, see the Results section. A, Kaplan-Meier plot of OS for 590 surgically treated lung adenocarcinoma patients
combined from the five validation datasets stratified by concordant or discordant NCC and SSP2 classifications. B, OS for 94 of 104 patients with
discrepant SSP2/NCC classification from (A). C, DMFS for 454 surgically treated lung adenocarcinoma patients combined from the five validation
datasets stratified by concordant or discordant NCC and SSP2 classifications. D, Kaplan-Meier plot of DMFS for 86 patients with discrepant
SSP2/NCC classification from (C). E, Kaplan-Meier plot of OS for 176 lung adenocarcinoma patients treated with adjuvant chemotherapy
combined from the five validation datasets. F, DMFS for 105 adjuvant treated lung adenocarcinoma patients combined from the five validation
datasets. In all plots, P-values were calculated using the log-rank test
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Survival analysis of this selective Stage I cohort showed that
CLAMS stratified patients into better and worse prognosis (log-rank
P = .02, HR = 3.2, 95% CI = 1.2-8.8), with a 4-year relapse-free rate of
82% for the TRU group, while only 41% for the nonTRU group
(Figure 4F). In multivariable analysis, CLAMS remained significant
when using gender, age and Stage IA/IB as covariates (HR = 3.3, 95%
CI = 1.04-10.5), and borderline nonsignificant when including also
smoking status (never/smoker) in the model (P = .06).
In a second validation, we applied CLAMS to 30 FFPE Stage-I
tumors with RNA sequencing data (GSE143486). CLAMS stratified
patients into better and worse survival (Figure 4G) and remained sig-
nificant in multivariable analysis (nonTRU, HR = 8.8, 95% CI = 2.2-34)
using age, gender and Stage IA/IB as covariates and OS as clinical
endpoint.
4 | DISCUSSION
In the current study, we present a gene expression-based classifier of
lung AC molecular subtypes applicable to single samples irrespectively
TABLE 2 Cox regression analysis of transcriptional subtypes in lung adenocarcinoma (surgically treated patients)
Univariable analysis Multivariable analysisa
Events (N) HR 95% CI P* Events (N) HR 95% CI P* Included confoundersa
Overall survivalb
Subtypesc 159/590 157/586
TRU-TRU 1.00 Ref (<.001) 1.00 Ref (<.001) Stage, gender, age
TRU-nonTRU 2.9 1.37-6.32 .005 3.0 1.38-6.42 .005
nonTRU-TRU 0.69 0.32-1.48 .3 0.76 0.35-1.65 .5
nonTRU-nonTRU 3.3 2.30-4.84 <.001 2.9 1.92-4.23 <.001
Stage 157/586
I 1.00 Ref (<.001) 1.00 Ref
II 3.1 2.17-4.41 <.001 2.5 1.73-3.61 <.001
III 7.2 4.66-11.10 <.001 5.4 3.46-8.41 <.001
Gender 159/590
Female 1.00 Ref (.3) 1.00 Ref
Male 1.2 0.87-1.61 .3 0.96 0.70-1.33 .8
Age (yr) 159/590
1.04 1.02-1.06 (<.001) 1.03 1.01-1.05 <.001
Distant metastasis-free survivald
Subtypesc 146/454 145/452
TRU-TRU 1.00 Ref (<.001) 1.00 Ref (<.001) Stage, gender, age
TRU-nonTRU 3.0 1.38-6.39 .005 3.0 1.39-6.52 .005
nonTRU-TRU 1.8 1.06-3.02 .03 1.4 0.77-2.35 .2
nonTRU-nonTRU 2.8 1.88-4.15 <.001 2.1 1.37-3.21 <.001
Stage 145/452
I 1.00 Ref (<.001) 1.00 Ref
II 3.2 2.28-4.58 <.001 2.8 1.89-4.02 <.001
III 3.3 1.71-6.39 <.001 3.0 1.48-5.65 .001
Gender 146/454
Female 1.00 Ref (.3) 1.00 Ref
Male 1.2 0.87-1.66 .3 1.1 0.77-1.49 .7
Age (yr) 146/454
1.02 1.002-1.04 (.03) 1.02 1.01-1.05 .02
Abbreviation: CI, confidence interval.
aThe following confounders were included in the model: Stage (not Stage IV because of too few cases), gender and age. The confounders were selected
based on their significance from the univariable analysis with P ≤ .05 (except for gender).
bFollow-up starts after surgical resection of the tumor lesion and ends at death by any reason (=event).
cGroups were created based on a combination of two classifiers' outcome: TRU or nonTRU. Classifier1 (=NCC) − Classifier2 (=SSP).
dFollow-up starts after surgical resection of the tumor lesion and ends at distant metastasis occurrence (=event).
*P-value for the pairwise comparisons were calculated using the Wald test. Overall P-values (also from the Wald test) are given within the parentheses.
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of technical platform or cohort composition. Moreover, the classifier
represents an independent prognostic assessment tool for surgically
treated tumors in this disease and can be translated into an assay
applicable for routine clinical tissue.
The SSP2 TRU/nonTRU and the SSP3 TRU/PI/PP models both
included cell proliferation as a significant biological process, in line
with our previous findings of expression of proliferation-related genes
representing the main prognostic component in the NCC model.13
Moreover, the functional analyses of SSP models demonstrate that
SSP machine-learning using thousands of genes can identify biologi-
cally relevant features that can be grouped into interpretable biologi-
cal processes.
Overall, we observed an accuracy of 0.85 for the SSP2 and 0.81
for the SSP3 models based on all validation samples (irrespective of
disease stage). However, one has to bear in mind that the SSP models
were trained on molecular assignments obtained by the NCC method,
which itself comprises inherited robustness problems.13 Specifically,
the NCC subtype training labels are not optimal for certain cohorts,
due to a cohort composition different from that in which the original
NCC centroids were derived. Illustrating this, notable differences in
the proportion of TRU-classified samples were observed between the
NCC and SSP classifiers for specific validation datasets (Figure 2D),
most prominently in the Okayama et al dataset.48 This dataset con-
sists of 74% Stage-I tumors, and patients in this dataset have been
shown to have a generally very good prognosis.15 Thus, in this con-
text, NCC classification infers a predicted poor outcome class (ie, non-
TRU) to patients with an intrinsically good prognosis due to the
prerequisite of gene-centering in the NCC model. In contrast, SSP
classifiers appear able to handle cohort composition bias due to their
ability to classify samples truly independently. These findings illustrate
the benefits of gene expression-based SSPs in a possible clinical con-
text if there are no standardized relevant reference datasets for gene-
centering available.
The proposed TRU, PI and PP subtypes have been associated
with different molecular and clinicopathological characteristics,4,9,13
and we also demonstrate an association with histological growth pat-
terns of lung AC. The perhaps most clinically useful feature of the
expression subtypes is their association with patient outcome in early
stage (operable) disease.13 While we find that both TRU/nonTRU
NCC and SSP2 classifications are associated with patient outcome in
early stage patients, actual patient outcome favors the SSP2 classifica-
tion for discordantly classified cases. This observation is crucial in the
context of SSP applicability, allowing a platform agnostic gene
signature to be applied to individual patients without any data
preprocessing or reference cohorts. Functional analyses of SSP2 and
SSP3 suggest that, in a prognostic context, these predictors provide a
relative division between low- and (more) high-proliferative tumors.
Application of the SSP2 model to 504 squamous cell lung carcinomas
assembled from public datasets22 classified 96% of tumors as non-
TRU, without any prognostic association (exploratory analysis, Supple-
mentary Figure S4). This opposite result compared to AC is likely due
to an intrinsically higher proliferation rate in squamous tumors com-
pared to AC tumors (shown by, eg, Reference 49). This further illus-
trates the differences in underlying prognostic gene expression
components in the histological subtypes of lung cancer, which could
be one of the reasons underlying the difficulty in validating gene sig-
natures from NSCLC studies of mixed histologies in histology specific
cohorts.15
While a gene signature predictive of response to chemotherapy is
highly desirable in resected lung AC, our results do not support that
the proposed molecular subtypes currently seem to match that need.
Instead, the current potential clinical value of our derived predictors
lies in improved risk stratification of surgically treated Stage-I patients.
This risk stratification could aid in identifying patient subsets for
which, on a group level, additional adjuvant treatment appears less
motivated (TRU-cases). For remaining patients (nonTRU), it may be
argued that additional adjuvant treatment could be considered. Ide-
ally, such claims need to be supported by randomized trial data that
investigates the benefit of additional adjuvant treatment to otherwise
untreated patients stratified by the molecular assay. Such studies
have, to date, not been reported in lung cancer, in contrast to, for
example, breast cancer.50 To allow for the latter, robust assays appli-
cable to degraded RNA from fixated tissue are needed. This has repre-
sented a challenge for introducing gene expression-based signatures
into the clinic. As a countermeasure, focused gene expression
methods, such as the NanoString nCounter technique, have been used
in breast cancer (the ProSigna test). To address the requirement of
analyzing degraded RNA, we paired our SSP2 model (CLAMS) with
the NanoString nCounter XT technology forming a “complete” assay.
In FFPE RNA from 44 Stage-I patients, we could demonstrate that the
assay could recapitulate SSP2 gene rules, and that NanoString gene
expression was representative of the expected subgroups. These
results were supported also by application of the SSP2 model to FFPE
RNA sequencing data. Together, these findings show, to the best of
our knowledge for the first time in lung cancer, that in silico derived
SSP rules can be transferred to an FFPE applicable assay. In the
F IGURE 4 SSP2 performance on surgically treated Stage-I lung adenocarcinomas. A, Kaplan-Meier plot of OS for surgically treated Stage-I
patients in the validation datasets (only patients with outcome data), stratified by SSP2 classification. B, DMFS for surgically treated Stage-I
patients in the validation datasets, stratified by SSP2 classification. C, Hierarchical clustering (Pearson correlation and ward.D linkage) of log2
count NanoString data for 44 FFPE Stage-I tumors using the 36 genes present in the SSP2 model through the CLAMS package. D, Confusion
matrix of CLAMS prediction vs clinical status of relapse (loc-regional/distant) yes/no. E, Gene expression of MKI67 (Ki67) and NAPSA (Napsin A)
across the 44 NanoString cases stratified by CLAMS prediction and clinical relapse status. Groups in gray represents agreement between TRU/no
relapse and nonTRU/relapse. F, Kaplan-Meier plot of recurrence-free (loco-regional/distant) interval for the 44 NanoString cases stratified by
CLAMS prediction. G, Kaplan-Meier plot of OS for 30 Stage-I tumors from GSE143486 stratified by CLAMS prediction. FFPE RNA for these
samples were analyzed by RNA sequencing. In all Kaplan-Meier plots, P-values were calculated using the log-rank test
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selected set of 44 analyzed patients (ie, not population-representa-
tive), the assay translated into a significant difference in recurrence-
free interval, with a similar 4-year recurrence-free outcome as in the
in silico validation cohort (Figure 4). While SSP performance in the
FFPE cohort could desirably have been higher, one should bear in
mind that, at present, there is a shortage of clinical risk stratification
tools for patients with lowest disease stage subjected to curative sur-
gery, and for whom current guidelines do not recommend adjuvant
therapy. Moreover, surgical treatment may of course cure patients
with high-proliferative tumors (nonTRU) that have not yet metasta-
sized, whereas low-proliferative tumors (TRU) may have acquired
metastatic potential early in their development. Such instances repre-
sent limitations for prognostic gene expression models based on surgi-
cal specimens.
In summary, we have derived platform independent single sample
gene expression classifiers of proposed transcriptional subtypes in
lung AC that also provides risk stratification in surgically treated
Stage-I patients. Our SSP2 and SSP3 models now allow unrestricted
usage of the TCGA subtypes even in highly selected lung AC cohorts,
including advanced stage tumors. In malignancies such as breast can-
cer, gene expression signatures have now made their way into clinical
practice to support clinical decision-making about adjuvant therapy.
Whether a similar development will occur in early stage lung AC
remains to be seen. However, robust gene expression predictors that
have been translated into actual assays is an important first step in
demonstrating that a similar development may be worthwhile
exploring.
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